Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04337840
Other study ID # 202003047RINA
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 5, 2020
Est. completion date March 2022

Study information

Verified date March 2020
Source National Taiwan University Hospital
Contact Jen-Yu Hsu
Phone 0922868936
Email b94401012@g.ntu.edu.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Nosocomial infections are increasing rapidly both internationally and domestically, especially carbapenem-resistant Klebsiella pneumoniae infections. However, there were still lack of evidence about the risk and prognosis in Taiwan. The choice of drug and related sensitivity test was also limited. We would analyze the infection risk, prognosis, and drug sensitivity of Klebsiella pneumoniae and focus on strategy to manage carbapenem-resistant Klebsiella pneumoniae infections.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date March 2022
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years to 100 Years
Eligibility All adult patients (=18 years) with K. pneumoniae bloodstream infection were included. Patients were excluded if there was other recognized bacteremia within two weeks before or after the first episode of K. pneumoniae bloodstream infection.

Study Design


Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary All-cause 28-day mortality 2017-2019